Deutsche Bank set a $275.00 target price on Illumina (NASDAQ:ILMN) in a research report report published on Tuesday, January 16th. The brokerage currently has a buy rating on the life sciences company’s stock.
ILMN has been the topic of several other reports. Vetr raised shares of Illumina from a hold rating to a buy rating and set a $217.50 price target on the stock in a research report on Tuesday, September 19th. Goldman Sachs Group reissued a neutral rating and set a $200.00 price target on shares of Illumina in a research report on Tuesday, September 26th. Piper Jaffray Companies reissued an overweight rating and set a $226.00 price target (up from $202.00) on shares of Illumina in a research report on Monday, October 9th. Canaccord Genuity reaffirmed a buy rating and issued a $230.00 target price (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Finally, Janney Montgomery Scott raised shares of Illumina from a sell rating to a neutral rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. Illumina presently has an average rating of Buy and an average target price of $241.39.
Shares of Illumina (NASDAQ:ILMN) traded up $7.65 during mid-day trading on Tuesday, hitting $217.19. 1,679,191 shares of the stock traded hands, compared to its average volume of 1,100,000. Illumina has a one year low of $158.02 and a one year high of $248.97. The firm has a market cap of $31,710.00, a price-to-earnings ratio of 44.05, a price-to-earnings-growth ratio of 2.87 and a beta of 0.92. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.22. The firm had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The company’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.85 EPS. sell-side analysts predict that Illumina will post 4.59 earnings per share for the current year.
In related news, EVP Marc Stapley sold 2,000 shares of Illumina stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $216.87, for a total transaction of $433,740.00. Following the completion of the transaction, the executive vice president now owns 27,952 shares of the company’s stock, valued at $6,061,950.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $230.82, for a total transaction of $692,460.00. Following the completion of the sale, the director now owns 19,868 shares of the company’s stock, valued at $4,585,931.76. The disclosure for this sale can be found here. Insiders have sold 118,922 shares of company stock valued at $26,245,549 in the last ninety days. Insiders own 0.89% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Alexandria Capital LLC purchased a new position in Illumina during the fourth quarter worth about $1,696,000. Markel Corp purchased a new position in Illumina during the fourth quarter worth about $218,000. Norinchukin Bank The boosted its holdings in Illumina by 7.4% during the fourth quarter. Norinchukin Bank The now owns 11,672 shares of the life sciences company’s stock worth $2,550,000 after purchasing an additional 805 shares during the last quarter. American International Group Inc. boosted its holdings in Illumina by 8.0% during the fourth quarter. American International Group Inc. now owns 64,392 shares of the life sciences company’s stock worth $14,069,000 after purchasing an additional 4,776 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Illumina by 58.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 257,000 shares of the life sciences company’s stock worth $56,152,000 after purchasing an additional 94,600 shares during the last quarter. Hedge funds and other institutional investors own 92.09% of the company’s stock.
WARNING: “Illumina (ILMN) Given a $275.00 Price Target at Deutsche Bank” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2018/02/12/illumina-ilmn-given-a-275-00-price-target-by-deutsche-bank-analysts.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.